Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination with Liposomal Doxorubicin in Patients with Ovarian Cancer or Other Advanced Solid Tumors

Trial Profile

An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination with Liposomal Doxorubicin in Patients with Ovarian Cancer or Other Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STM 434 (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 08 May 2019 Results published in the Clinical Cancer Research
    • 10 Feb 2017 Status changed from recruiting to completed.
    • 08 Aug 2016 According to an Atara Biotherapeutics media release, the company plans to begin the monotherapy dose expansion component of this trial by the end of 2016 in patients with advanced granulosa cell or clear cell ovarian cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top